查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
良性前列腺增生治疗市场规模、份额及成长分析（治疗方法、类型、产品、最终用户及地区划分）－2026-2033年产业预测
市场调查报告书
商品编码
1897629

良性前列腺增生治疗市场规模、份额及成长分析（治疗方法、类型、产品、最终用户及地区划分）－2026-2033年产业预测

Benign Prostatic Hyperplasia Treatment Market Size, Share, and Growth Analysis, By Treatment (Minimal Invasive Surgery, Invasive Surgery), By Type (Drug Treatment, Surgical Treatment), By Product, By End User, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

全球良性前列腺增生治疗市场规模预计在 2024 年达到 120.8 亿美元，从 2025 年的 127.4 亿美元增长到 2033 年的 195.6 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.5%。

全球良性前列腺增生（BPH）治疗市场受多种关键因素驱动。人口老化导致BPH盛行率不断上升，使得寻求有效治疗方法的患者群体日益扩大。这推动了对创新微创治疗方法的需求，例如经尿道前列腺切除术、雷射治疗和前列腺动脉栓塞术，这些疗法有望缩短恢復时间并减少併发症。透过公共卫生措施和宣传宣传活动提高大众对BPH的认识，进一步促进了早期诊断和治疗，从而导致对各种治疗方案的需求激增。此外，政府的支持性政策和优惠的报销制度也推动了先进BPH治疗方法，对市场扩张产生了正面影响。

推动全球良性前列腺增生治疗市场发展的因素

人们对良性前列腺增生（BPH）及其相关症状的认识不断提高，促进了该疾病的早期发现和诊断。这种认知的提升得益于政府、医疗机构和倡议团体共同进行的宣传宣传活动和筛检计画。对及时介入和有效治疗的重视不仅改善了患者的预后，也对BPH治疗市场的扩张起到了关键作用。随着人们对自身健康的了解和关注度不断提高，对有效治疗方法的需求显着增长，进一步推动了市场发展。

限制全球良性前列腺增生治疗市场的因素

由于专利到期，学名药的涌入，全球良性前列腺增生（BPH）治疗市场面临严峻挑战。这些学名药，包括α受体阻断剂和5α还原酶抑制剂，加剧了市场竞争，并对品牌药的价格造成下行压力。随着越来越多的患者选择这些经济实惠的替代疗法，现有品牌药的市场收入可能会下降。这种价格承受能力的变化不仅影响消费者的选择，也改变了市场竞争的整体动态，最终对BPH治疗领域现有治疗方法的盈利构成威胁。

良性摄护腺增生治疗市场的全球趋势

全球良性前列腺增生 (BPH) 治疗市场正经历着向微创手术的显着转变，这反映了更广泛的医疗保健趋势，即更加重视患者舒适度和治疗效果。雷射消熔、经尿道前列腺切除术术 (TURP) 和前列腺尿道提升术 (PUL) 等技术因其诸多优势而迅速被接受，这些优势包括恢復时间更短、住院时间更短以及术后併发症率更低。这种对微创治疗方法的重视源于对以患者为中心的护理理念的日益关注，旨在提高 BPH 患者的生活品质 (QOL)，同时有效控制医疗成本。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二手资料和一手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2025）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析

全球良性前列腺增生治疗市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

  • 微创手术
  • 侵入性手术

全球良性前列腺增生治疗市场规模（按类型和复合年增长率划分）（2026-2033 年）

  • 药物治疗
    • α受体阻断剂
    • 阿夫唑嗪
    • 多沙唑嗪
    • Tamsulosin
    • 西洛多辛
    • 其他α受体阻断剂
    • 5α-还原酶抑制剂
    • 非那雄胺
    • 度他雄胺
    • 其他药物类别
  • 手术治疗
    • 经尿道膀胱镜摄护腺切除术（TURP）
    • 经尿道微波热疗（TUMT）
    • 经尿道针消融术（TUNA）
    • 雷射疗法
    • 摄护腺支架置入术
    • Urolift疗法
    • 瑞祖姆疗法
    • 其他手术

全球良性前列腺增生治疗市场规模（按产品和复合年增长率划分）（2026-2033 年）

  • 电切镜
  • 泌尿系统雷射
  • 射频消融术
  • 电极
  • 导管
  • 摄护腺支架
  • 植入
  • 其他的

全球良性前列腺增生治疗市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

  • 家庭医疗保健
  • 医院和诊所
  • 研究与製造

全球良性前列腺增生治疗市场规模及复合年增长率（2026-2033）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2025 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2025 年）
  • 主要企业公司简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2023-2025年营收年比比较

主要企业简介

  • Boston Scientific Corporation（USA）
  • Pfizer Inc.（USA）
  • GlaxoSmithKline plc（UK）
  • Eli Lilly and Company（USA）
  • Abbott Laboratories（USA）
  • Astellas Pharma Inc.（Japan）
  • Sanofi SA（France）
  • Merck & Co., Inc.（USA）
  • Teleflex Incorporated（USA）
  • Olympus Corporation（Japan）
  • Coloplast Group（Denmark）
  • Asahi Kasei Corporation（Japan）
  • Allergan plc（Ireland）
  • IPG Photonics Corporation（USA）
  • Richard Wolf GmbH（Germany）
  • Biolitec AG（Austria）
  • Urologix, LLC（USA）
  • Procept BioRobotics Corporation（USA）
  • Lumenis Ltd.（Israel）
  • KARL STORZ SE & Co. KG（Germany）

结论与建议

简介目录
Product Code: SQMIG35E2045

Global Benign Prostatic Hyperplasia Treatment Market size was valued at USD 12.08 Billion in 2024 and is poised to grow from USD 12.74 Billion in 2025 to USD 19.56 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The global market for benign prostatic hyperplasia (BPH) treatment is being driven by several key factors. An increase in the prevalence of BPH, attributed to a growing aging population, has expanded the patient demographic seeking effective solutions. This has spurred demand for innovative and minimally invasive treatments, such as transurethral resection of the prostate, laser therapy, and prostatic artery embolization, which offer shorter recovery times and reduced complications. Enhanced awareness of BPH through public health initiatives and educational campaigns has further contributed to early diagnosis and treatment, resulting in a surge in demand for various treatment options. Additionally, supportive government policies and favorable reimbursement frameworks are boosting the adoption of advanced BPH therapies, positively influencing market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Benign Prostatic Hyperplasia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Benign Prostatic Hyperplasia Treatment Market Segments Analysis

Global Benign Prostatic Hyperplasia Treatment Market is segmented by Treatment, Type, Product, End User and region. Based on Treatment, the market is segmented into Minimal Invasive Surgery and Invasive Surgery. Based on Type, the market is segmented into Drug Treatment and Surgical Treatment. Based on Product, the market is segmented into Resectoscopes, Urology Laser, Radiofrequency Ablation, Electrodes, Catheters, Prostatic Stents, Implants and Others. Based on End User, the market is segmented into Home Healthcare, Hospitals & Clinics and Research & Manufacturing. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Benign Prostatic Hyperplasia Treatment Market

The increasing awareness surrounding benign prostatic hyperplasia (BPH) and its related symptoms is facilitating earlier detection and diagnosis. This heightened understanding is driven by the concerted efforts of governments, healthcare organizations, and advocacy groups, which are implementing campaigns and screening programs to raise awareness about the condition. The focus on prompt intervention and effective treatment not only enhances patient outcomes but also plays a crucial role in the expansion of the BPH treatment market. As individuals become more informed and proactive regarding their health, the demand for effective therapies significantly increases, further fueling market growth.

Restraints in the Global Benign Prostatic Hyperplasia Treatment Market

The Global Benign Prostatic Hyperplasia Treatment market faces significant restraints due to the expiration of patents, which has enabled the introduction of generic medications. These generics, including alpha-blockers and 5-alpha reductase inhibitors, have created a competitive environment that places downward pressure on the pricing of branded products. As patients increasingly opt for these cost-effective alternatives, market revenues for established brands may decline. This shift towards affordability not only impacts consumer choices but also alters the overall dynamics of market competition, ultimately challenging the profitability of existing treatment options in the BPH sector.

Market Trends of the Global Benign Prostatic Hyperplasia Treatment Market

The Global Benign Prostatic Hyperplasia (BPH) Treatment market is witnessing a significant shift towards minimally invasive procedures, reflecting a broader trend in healthcare prioritizing patient comfort and outcomes. Techniques such as laser ablation, transurethral resection of the prostate (TURP), and prostatic urethral lift (PUL) are rapidly gaining acceptance due to their advantages, including shorter recovery times, reduced hospital stays, and a lower incidence of postoperative complications. This emphasis on less invasive treatment options is fueled by a growing commitment to patient-centered care, which aims to enhance the overall quality of life for individuals suffering from BPH, while simultaneously addressing the imperative to manage healthcare costs effectively.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Benign Prostatic Hyperplasia Treatment Market Size by Treatment & CAGR (2026-2033)

  • Market Overview
  • Minimal Invasive Surgery
  • Invasive Surgery

Global Benign Prostatic Hyperplasia Treatment Market Size by Type & CAGR (2026-2033)

  • Market Overview
  • Drug Treatment
    • Alpha Blockers
    • Alfuzosin
    • Doxazosin
    • Tamsulosin
    • Silodosin
    • Other Alpha Blockers
    • 5-Aplha Reductase Inhibitors
    • Finasteride
    • Dutasteride
    • Other Drug Classes
  • Surgical Treatment
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Microwave Thermotherapy (TUMT)
    • Transurethral Needle Ablation of the Prostate (TUNA)
    • Laser Therapy
    • Prostatic Stenting
    • UroLift Therapy
    • Rezum Therapy
    • Other Surgeries

Global Benign Prostatic Hyperplasia Treatment Market Size by Product & CAGR (2026-2033)

  • Market Overview
  • Resectoscopes
  • Urology Laser
  • Radiofrequency Ablation
  • Electrodes
  • Catheters
  • Prostatic Stents
  • Implants
  • Others

Global Benign Prostatic Hyperplasia Treatment Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Home Healthcare
  • Hospitals & Clinics
  • Research & Manufacturing

Global Benign Prostatic Hyperplasia Treatment Market Size & CAGR (2026-2033)

  • North America (Treatment, Type, Product, End User)
    • US
    • Canada
  • Europe (Treatment, Type, Product, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Treatment, Type, Product, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Treatment, Type, Product, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Treatment, Type, Product, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Boston Scientific Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott Laboratories (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi S.A. (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teleflex Incorporated (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Olympus Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Coloplast Group (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Asahi Kasei Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan plc (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • IPG Photonics Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Richard Wolf GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biolitec AG (Austria)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Urologix, LLC (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Procept BioRobotics Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lumenis Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • KARL STORZ SE & Co. KG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations